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Irinotecan (CPT-11) is an anticancer agent for the treatment of colon cancer. CPT-11 can be considered as a prodrug, since it
needs to be activated into the toxic drug SN-38 by the enzyme carboxylesterase. An approach to achieve tumour speciﬁc
activation of CPT-11 is to transduce the cDNA encoding carboxylesterase into tumour cells. A secreted form of
carboxylesterase may diffuse through a tumour mass and may activate CPT-11 extracellularly. This could enhance the
antitumour efﬁcacy by exerting a bystander effect on untransduced cells. In addition a secreted tumour-targeted form of
carboxylesterase should prevent leakage of the enzyme from the site of the tumour into the circulation. We have constructed
a secreted form of human liver carboxylesterase-2 by deletion of the cellular retention signal and by cloning the cDNA
downstream of an Ig kappa leader sequence. The protein was secreted by transfected cells and showed both enzyme activity
and efﬁcient CPT-11 activation. To obtain a secreted, tumour-targeted form of carboxylesterase-2 the cDNA encoding the
human scFv antibody C28 directed against the epithelial cell adhesion molecule EpCAM, was inserted between the leader
sequence and carboxylesterase-2. This fusion protein showed CPT-11 activation and speciﬁc binding to EpCAM expressing
cells. Importantly, in combination with CPT-11 both recombinant carboxylesterase proteins exerted strong antiproliferative
effects on human colon cancer cells. They are, therefore, promising new tools for gene directed enzyme prodrug therapy
approaches for the treatment of colon carcinoma with CPT-11.
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Conventional chemotherapy lacks speciﬁcity for tumour cells. This
results in dose-limiting side effects and insufﬁcient concentrations
of the drugs in the tumour, through which efﬁcacy is limited
and drug resistant cellular subpopulations may emerge. These
problems may be overcome by expressing an enzyme that is
capable of converting a non-toxic prodrug into a toxic drug speci-
ﬁcally in tumour cells. This so-called gene-directed enzyme
prodrug therapy (GDEPT) or suicide gene therapy aims to increase
the concentration of the drug in the tumour while reducing the
systemic toxicity. The gene encoding the prodrug-activating
enzyme is delivered to the tumour cells by, for example, an adeno-
viral vector, followed by systemic administration of the prodrug. In
this regard, several prodrug-converting enzymes have been exten-
sively studied, such as the herpes simplex virus thymidine kinase
enzyme that converts ganciclovir (GCV) into the active compound
GCV-P and bacterial cytosine deaminase that activates 5-FC to the
anticancer drug 5-FU (Moolten, 1986; Austin and Huber, 1993).
A prodrug for the treatment of colon carcinoma is irinotecan
(CPT-11 or 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonylox-
ycamptothecin). CPT-11 is converted by carboxylesterases (CE)
into the toxic drug SN-38 (7-ethyl-10-hydroxycamptothecin) by
cleavage of the bulky dipiperidino side chain at the carbon position
(Tsuji et al, 1991; Satoh et al, 1994). CPT-11 has demonstrated
antitumour activity in immune deprived animals bearing human
tumour xenografts (Houghton et al, 1995, 1996; Thompson et al,
1997a,b) and is approved for use in the treatment of metastatic
colorectal cancer in humans. Although SN-38 can be detected in
the plasma of cancer patients only minutes after the administration
of CPT-11 (Gupta et al, 1997), 90% of the administered CPT-11 is
not converted to SN-38 (Rivory et al, 1997).
CEs are a ubiquitously expressed class of enzymes. High levels of
enzyme activity are found in human liver and lung (Satoh and
Hosokawa, 1998). Different isoforms of human CE have been
described. CE1 is found in liver only, whereas CE2 is also found
in the intestines and CE3 is found in brain cells (Hojring and
Svensmark, 1977; Ketterman et al, 1989). Furthermore, it has been
shown that human alveolar macrophages release a serine esterase
that is identical to liver CE1 (Munger et al, 1991).
Several studies have been performed using CPT-11 in combina-
tion with human CE1 in a GDEPT approach. Kojima et al
(1998a,b) described the construction of a replication deﬁcient
adenoviral vector containing the human liver CE1 gene driven by
the CMV promoter. In vitro results showed that several tumour cell
lines infected with this virus express CE1 and in the presence of
CPT-11 tumour growth was effectively suppressed. However, on
many other tumour cell lines only minimal effects were observed.
This underscored the notice that the success of a GDEPT approach
for CPT-11 requires an enzyme with a high efﬁciency of converting
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www.bjcancer.comCPT-11 to SN-38. The rabbit CE was found to be 100–1000-fold
more efﬁcient in converting CPT-11 than human liver CE1 and
was 12–55-fold more efﬁcient in sensitising transfected cells to
CPT-11 (Danks et al, 1999). Therefore, an adenoviral vector
expressing rabbit CE was constructed and transduction of human
tumour cells led to sensitisation to CPT-11 (Wierdl et al, 2001).
The disadvantage of rabbit CE, however, is that expression of a
nonhuman protein in patients may lead to an immunological
response and subsequent enzyme inactivation. A human enzyme
with higher afﬁnity and higher efﬁciency than CE1 may overcome
these limitations. It was shown that human CE2 has a higher afﬁ-
nity and a higher conversion velocity for CPT-11 than CE1
(Humerickhouse et al, 2000). Therefore, we envisaged that CE2
would be a candidate to employ in a GDEPT approach to treat
human tumours.
To achieve efﬁcient kill of all tumour cells, a bystander effect is
required, whereby CPT-11 is cleaved to SN-38 that not only kills
the tumour cells in which CE2 is formed, but also neighbouring
tumour cells that do not express CE2. We hypothesised that extra-
cellular conversion of CPT-11 would lead to a larger bystander
effect than intracellular conversion and, furthermore, that a fusion
protein consisting of secreted CE2 fused to a tumour speciﬁc scFv
antibody will be retained in the tumour thereby preventing leakage
of the enzyme into the circulation and therefore further reducing
unwanted side effects.
In this study we describe the construction of a secreted form of
CE2 (sCE2) by deletion of a C-terminal cellular retention signal
and by adding the Ig kappa leader sequence. Furthermore, a
secreted targeted form of human CE2 (C28-sCE2) was constructed
by fusing sCE2 to a human scFv directed against Epithelial Cell
Adhesion Molecule (EpCAM), a tumour-associated antigen. The
binding speciﬁcity and enzyme activity of the secreted form of
CE2 and the fusion protein and their ability to sensitise human
tumour cell lines to CPT-11 is determined and compared to wild-
type intracellularly expressed human CE2 (CE2).
MATERIALS AND METHODS
Chemicals
Pwo polymerase, PCR buffer and dNTPs were obtained from
Roche (Almere, The Netherlands). Restriction enzymes were
purchased from New England Biolabs (Beverly, MA, USA) and Life
Technologies (Breda, The Netherlands). The kits used for DNA
isolation, puriﬁcation and extraction from agarose gel were from
Qiagen (Hilden, Germany). The substrate p-nitrophenyl-acetate
was purchased from Sigma-Aldrich (Zwijndrecht, The Nether-
lands). The prodrug CPT-11 and the drug SN-38 were obtained
from Rho ˆne-Poulenc Rorer (Vitry-sur-Seine, France).
Cell lines
The COS-7 and the human colon cancer SW1398 cell lines were
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM, Life
Technologies, Paisley, UK) supplemented with 5% (COS-7) or
10% heat-inactivated foetal calf serum (Life Technologies),
50 IU ml
71 penicillin (Life Technologies) and 50 mgm l
71 strepto-
mycin (Life Technologies) in a humidiﬁed atmosphere containing
5% CO2 at 378C.
Construction of psCE2 and pC28-sCE2
The pBluescript vector containing the CE2 open reading frame
(Sone and Wang, 1997) was digested with EcoRI and the CE2
encoding fragment was ligated into the EcoRI linearised eukaryotic
expression vector pcDNA3 (Invitrogen, Groningen, The Nether-
lands). This construct was called pCE2. To construct a secreted
form of CE2 (psCE2), two primers (sense 5'-GACGCGGCC-
CAGCCGGCCCAGGACTCAGCCAGTCCCATCC-3' and antisense
5'-GACTCGAGCGGCCGCTCTCTCTTCAGGCTCCTCGAGC-3')
were designed to introduce an SﬁI restriction site (italic) at the
beginning of the sequence encoding the mature protein and a NotI
restriction site (italic) before the retention signal, as shown in
Figure 1. After performing the PCR, the SﬁI/NotI digested fragment
was isolated, puriﬁed, and ligated into the eukaryotic expression
vector pSTCF, containing a myc- and 6 his-tag and the Ig kappa
leader sequence that directs proteins to the secretory pathway
(Arafat et al, 2000).
The human anti-EpCAM scFv C28 was derived from scFv UBS-
54, which was isolated from a semi-synthetic phage antibody
display library (Huls et al, 1999), and was a kind gift of Dr T
Logtenberg (Crucell, Leiden). An SﬁI/NotI fragment encoding the
scFv C28 was isolated from a pHEN vector, and cloned into the
eukaryotic expression vector pSTCF. A ﬂexible (Gly4Ser)2 linker
was introduced downstream of C28, as described previously (de
Graaf et al, 2002). To allow insertion of sCE2 downstream of the
(Gly4Ser)2 linker, a PCR was performed to obtain a DNA fragment
encoding a secreted form of CE2 starting from the mature CE2
protein and ending just before the cellular retention signal. Both
primers used in the PCR (sense 5'-GTGTGCGGCCGCCAGGACT-
CAGCCAGTCCCATC-3' and antisense primer as described above)
contained a NotI site (italic). The PCR product was digested with
NotI and inserted into the NotI sites of the vector containing C28
with the (Gly4Ser)2 linker to obtain pC28-sCE2.
Expression of CE2, sCE2 and C28-sCE2 fusion protein
COS-7 cells (2610
6) were transfected with 2 mg pCE2, psCE2 or
pC28-sCE2 by Lipofectamine Plus reagent (Life Technologies)
according to instructions of the manufacturer. Cells were grown
in 3.5 ml DMEM containing 5% FCS and antibiotics. After 48 h,
supernatants were removed and cells were harvested by trypsiniza-
tion. Cellular lysates were obtained by three times freeze thawing in
350 ml PBS. For cytotoxicity assays and HPLC analysis proteins
present in supernatants of transfected COS-7 cells were 106
concentrated using a Biomax-10 centrifugal ﬁlter (Millipore,
Bedford, USA). Supernatants and cellular lysates were analysed
for the presence of functional CE enzyme or C28-sCE2 fusion
protein by Western blotting, esterase activity assay and cytotoxicity
assays. Binding of proteins in supernatants of COS-7 cells trans-
fected with pC28-sCE2 or psCE2 to EpCAM positive cells was
determined by FACS analysis.
Western blot analysis
Proportional amounts of supernatant or cellular lysates from
COS-7 cells transfected with pCE2, psCE2 or pC28-sCE2 were
dissolved in sample buffer (Laemmli, 1970) with 5% 2-mercap-
toethanol and heated at 958C for 5 min. Samples were
electrophoresed through a denaturing 10% sodium dodecyl
sulphate-polyacrylamide gel and protein bands were electroblotted
onto PVDF protein membrane (BioRad). Proteins were detected
using anti-myc antibody 9E10 (Chan et al, 1987) and HRP-conju-
gated rabbit anti-mouse IgG (Dako) or with rabbit-anti-CE2, an
antibody directed to the C-terminal retention signal of CE which
was a kind gift of Dr Yan, University of Rhode Island (Zhu et al,
2000), and HRP-conjugated swine anti-rabbit IgG (Dako). Blots
were developed with enhanced chemo luminescence reagent
(Lumilight Plus, Roche).
Esterase activity assay
Supernatants or cellular lysates of transfected COS-7 cells were
incubated with 200 ml 100 mM Tris-HCl pH 8.0 containing
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Nitrophenol was measured at a wavelength of 415 nm during
10 min using an ELISA plate reader (BioRad, Veenendaal, The
Netherlands).
FACS analysis
EpCAM expressing SW1398 cells were trypsinised for 5 min at
378C, washed with DMEM, counted and resuspended in PBS. A
total of 5610
5 cells was incubated for 1 h on ice with 50 ml super-
natant of COS-7 cells transfected with pC28-sCE2. As a negative
control, supernatants of untransfected COS-7 cells or cells trans-
fected with psCE2 were used. After washing three times with
PBS, cells were incubated with anti-myc antibody 9E10 in PBS/
0.1% BSA, washed three times with PBS, and stained with ﬂuores-
cein-conjugated rabbit anti-mouse IgG (Dako). As a positive
control 50 ml (10 mgm l
71) of the anti-EpCAM antibody 323/A3
(Edwards et al, 1986) was used. Stained cells were ﬁxed with 1%
formaldehyde in PBS and analysed on a FACScan ﬂow cytometer
(Becton Dickinson, Mountain View, CA, USA).
Immunohistochemistry
To show binding of C28-sCE2 to EpCAM expressing cells, 1610
4
SW1398 cells were plated and incubated overnight with the
concentrated supernatants of COS-7 cells transfected with psCE2
or pC28-sCE2. Unbound enzyme was removed by washing with
culture medium and cells were ﬁxed with 100 ml 50% MeOH/
50% acetone. After washing with PBS, anti-myc antibody 9E10
was added to the cells for 1 h at 378C, followed by incubation with
rabbit anti mouse HRP (1:100 in PBS/0.1%BSA) for 1 h. Hereafter
cells were washed and 3-amino-9-ethylcarbazole substrate chromo-
gen (Dako, USA) was added. The staining was stopped by washing
with PBS. Cells were counterstained with haematoxylin.
In vitro cytotoxicity assay
SW1398 cells (1610
4) were plated in a 96-well microtiter plate
(Bio-one). After 24 h, concentrated supernatants of COS-7 cells
transfected with pCE2, psCE2 or pC28-sCE2 was added together
with a non-toxic concentration of CPT-11 (1 mM). Control experi-
ments were performed in which SW1398 cells were incubated with
DMEM supplemented with 10% FCS, SN-38 or CPT-11 only. After
another 72 h culture the cells were incubated with cell proliferation
reagent WST-1 (Roche Diagnostics) for 1 h at 378C. The absor-
bency was measured at a wavelength of 450 nm. The
antiproliferative effects were determined and expressed as percen-
tages of growth as compared to untreated control growth, which
was set to 100%.
RESULTS
Construction of CE2, sCE2 and C28-sCE2
The cDNA coding for human CE2 (Sone and Wang, 1997) was
inserted into the eukaryotic expression vector pcDNA3, creating
pCE2 (Figure 1). Using PCR we ampliﬁed a CE2 cDNA fragment
encoding the mature protein without the last four amino acids
encoding the cellular retention signal HTEL. This fragment was
inserted into the pSTCF vector, which contains the Ig kappa leader
that directs the protein in the secretory pathway and a myc- and
6xhis-tag (Arafat et al, 2000). The resulting construct encoding a
secreted form of CE2 (sCE2) was designated psCE2 (Figure 1).
The cDNA fragment coding for sCE2 was also inserted into the
pSTCF vector in frame with the anti-EpCAM scFv C28, creating
pC28-sCE2 (Figure 1).
Expression and characterisation of CE2, sCE2 and
C28-sCE2
COS-7 cells were transfected with pCE2, psCE2 or pC28-sCE2 and
expressed proteins in supernatant and cellular lysates were analysed
by Western blotting, FACS analysis, esterase activity assay and
cytotoxicity assays. To assess the size of the expressed proteins
and determine the amount of secreted protein, SDS–PAGE was
performed followed by Western blotting and detection with anti-
myc antibody for sCE2 and C28-sCE2 or anti CE2 antibody for
CE2 (Figure 2). The CE2 protein appeared to remain intracellular
since it was only detected in the cellular lysate (Figure 2, lane 1) of
transfected COS-7 cells. Like CE2, the sCE2 monomers migrated
with an apparent molecular weight of 75 kDa. As expected, the
majority of sCE2 was detected in the supernatant of transfected
COS-7 cells, proving that deletion of the C-terminal retention
signal and fusing the Ig kappa leader, indeed directed the protein
into the secretory pathway (Figure 2, lane 5). The C28-sCE2 fusion
protein, with an apparent molecular weight of 100 kDa, was also
found mainly in the supernatants of transfected COS-7 cells
(Figure 2, lane 6).
Functional enzyme activity of CE2, sCE2 and C28-sCE2 was
demonstrated by an esterase enzyme activity assay (Figure 3). In
cells transfected with pCE2 esterase activity remained intracellular,
while in cells transfected with psCE2 or pC28-sCE2 almost all
activity was detected in the culture medium. These results
conﬁrmed the results of the Western blotting experiments, since
the relative amounts and the activities of CE2 proteins in cells
and supernatants of transfected COS-7 cells were comparable.
Binding of the C28-sCE2 fusion protein to EpCAM was
demonstrated by FACS analysis of EpCAM expressing SW1398
colon cancer cells incubated with transfected COS-7 supernatants
(Figure 4A), whereas sCE2 did not bind the EpCAM expressing
cells. Thus, the C28 moiety of C28-sCE2 mediated EpCAM bind-
ing. Furthermore, SW1398 cells were plated and incubated with
the transfected COS-7 supernatants for 24 h. Hereafter, cells were
stained with anti-myc antibody to detect bound fusion protein.
C28-sCE2 was detected at the membrane of SW1398 cells, shown
in Figure 4B, whereas cells incubated with sCE2 were not
stained.
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Figure 1 Schematic representation of the CE2, sCE2 and C28-sCE2
expression cassette. The CE2 cDNA is inserted as an EcoRI fragment into
pcDNA3. The encoded protein contains its wildtype N-terminal signal
peptide and a C-terminal cellular retention signal sequence HTEL. The
structural elements of pSTCF include the strong cytomegalovirus (CMV)
promoter, IgG kappa leader sequence, and a C-terminal myc- and
His-tag (mycHis) for easy detection and puriﬁcation. sCE2, without
retention signal, is inserted as a SﬁI/NotI fragment into pSTCF. The anti-Ep-
CAM scFv C28 is inserted as a SﬁI/NotI fragment. The gene encoding CE2 is
inserted as a NotI/NotI fragment, after the (Gly4Ser)2 linker is inserted in the
NotI and ApaI restriction sites.
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Concentrated supernatants of COS-7 cells transfected with pCE2,
psCE2 or pC28-sCE2 were analysed for CPT-11 conversion using
HPLC. Supernatants were incubated with CPT-11 for 22 h at
378C. It was found that both sCE2 and C28-sCE2, which were
secreted in the culture medium of transfected cells, were able to
activate the prodrug CPT-11, since the drug SN-38 was formed
(data not shown).
To show the effect of CPT-11 conversion into SN-38 by CE2,
sCE2 and C28-sCE2 on the viability of colon cancer cells, the
EpCAM-expressing colon carcinoma cell line SW1398 was incu-
bated overnight with the concentrated supernatant of COS-7 cells
transfected with pCE2, psCE2 or pC28-sCE2. After incubation,
culture medium or a non-toxic concentration (1 mM) of CPT-11
was added. In Figure 5 it is shown that the supernatants of
COS-7 cells transfected with sCE2 or C28-sCE2 render SW1398
cells susceptible to CPT-11. Incubation with supernatants of
pCE2 transfected COS-7 cells and CPT-11, which do not secrete
CE, or incubation with sCE2 or C28-sCE2 supernatant only, did
not show augmented toxicity.
DISCUSSION
CPT-11 is a prodrug for the treatment of colon cancer. One
enzyme that converts CPT-11 into the toxic drug SN-38 is CE.
By increasing the concentration of CE at the site of a tumour
via a GDEPT approach, the conversion of CPT-11 to SN-38 will
be enhanced at the site of the tumour, leading to tumour speciﬁc
cytotoxicity. Human liver CE1 and rabbit CE have been employed
in a GDEPT approach in combination with CPT-11. Although
rabbit CE appeared to convert CPT-11 very effectively (Danks et
al, 1999), an enzyme of human origin is preferred for in vivo appli-
cations to treat patients. Human CE1 showed a low conversion
velocity and a low hydrolysis rate for CPT-11 in comparison with
CE2 (Humerickhouse et al, 2000). Therefore, in this study we used
the human liver CE2 enzyme to sensitise human tumour cells to
CPT-11. Because current gene transfer technology does not allow
expression of transgenes in all cells of a targeted tumour in vivo,
a bystander effect is required, in order to achieve efﬁcient tumour
reduction. Extracellularly produced SN-38 should not only kill the
tumour cells in which CE2 is formed, but also neighbouring
tumour cells that do not express CE2. To investigate whether extra-
cellular conversion of CPT-11 would lead to a larger bystander
effect than intracellular conversion, we constructed a secreted form
of CE2 (sCE2). Furthermore, we hypothesised that a fusion protein
consisting of sCE2 fused to a tumour speciﬁc scFv antibody would
be retained in the tumour thereby preventing leakage of the
enzyme into the circulation and therefore further reducing
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Figure 2 Western blot analysis of the cellular lysates and supernatants of
COS-7 cells transfected with pCE, psCE2 or pC28-sCE2. sCE2 and C28-
sCE2 were detected using an antibody directed against the myc-tag and
CE2 was detected with an antibody directed against the C-terminal cellular
retention signal. In lanes 1, 3 and 4 cellular lysates (c) and in lanes 2, 5 and 6
supernatants (s) of COS-7 cells transfected with pCE2 (lanes 1,2), psCE2
(lanes 3,4) and pC28-sCE2 (lanes 5,6) respectively are shown. The CE
proteins migrated with an apparent molecular weight of 75 kDa whereas
the fusion protein had a molecular weight of 100 kDa. As expected, CE2
mainly remained intracellular while sCE2 and C28-sCE2 were secreted
by transfected COS-7 cells.
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Figure 3 CE-activity in cellular lysates and supernatants of COS-7 trans-
fected with pCE2, psCE2, pC28-sCE2. Cellular lysates or supernatants of
transfected COS-7 cells were incubated with 100 mM pNpAc and conver-
sion was measured during 10 min. sCE2 and C28-sCE2 show enzymatic
activity and are efﬁciently secreted by transfected cells, because most of
the enzyme activity is found in the supernatant.
C
o
u
n
t
s
0
8
0
1
6
0
2
4
0
3
2
0
4
0
0
100 101 102 103 104
FL1-Height
A
B
Figure 4 Binding of C28-sCE2 to the EpCAM expressing human colon
cancer cell line SW1398. (A) FACS analysis of SW1398 cells that highly
express EpCAM, with the supernatants of COS-7 cells transfected with
psCE2 or pC28-sCE2. As a positive control the 323A3 antibody (bold line),
directed to EpCAM was used. Binding was visualised with mouse anti-myc
antibody and ﬂuorescein-conjugated rabbit anti-mouse IgG. The fusion
protein C28-sCE2 (dotted line) is able to bind to SW1398 cells, whereas
sCE2 is overlapping the PBS control (solid line). (B) Cells were incubated
for 24 h with supernatants of transfected COS-7 cells. Hereafter, cells were
stained with anti-myc antibody to show binding of sCE2 or C28-sCE2 to
EpCAM. Cells were counterstained with haematoxylin. Only cells
incubated with C28-sCE2 (right) show binding of the fusion protein to
the cellular membrane, whereas sCE2 incubation did not show bound
protein (left).
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is EpCAM. This molecule is an attractive target for enzyme
prodrug therapy, since it is highly expressed on the cell surface
of most carcinomas, including colon tumours. Furthermore,
EpCAM is highly expressed on distant metastasis (Litvinov et al,
1994). Therefore, we constructed a fully human fusion protein
consisting of sCE2 fused to a human scFv antibody directed to
EpCAM (C28-sCE2). Intratumoural expression of this protein in
cancer patients is expected to be less immunogenic than expression
of non-human fusion proteins.
The secreted and the targeted protein were detected in the
supernatant of transfected COS-7 cells and the secreted proteins
exhibited comparable enzymatic activities as determined by conver-
sion of pNpAc. Comparing the secreted proteins to intracellular
wildtype CE2, it was observed that transfecting COS-7 cells with
pCE2 resulted in a much lower total amount of CE-activity than
cells transfected with psCE2 or the fusion protein C28-sCE2.
Whether this is due to a greater amount of protein or a higher
enzyme activity of sCE2 when compared with CE is not clear.
C28-sCE2 showed enzyme activity and speciﬁc binding to EpCAM
expressing cells as determined by FACS analysis and immunohisto-
chemistry on SW1398 cells, whereas sCE2 did not bind these cells.
Furthermore, using HPLC analysis it was shown that the secreted
as well as the targeted form of CE2 were able to efﬁciently convert
CPT-11 into SN-38. Experiments with SW1398 colon carcinoma
cells that were incubated with secreted or targeted protein and a
non-toxic concentration of CPT-11 showed complete growth inhi-
bition of these cells.
In conclusion, we constructed a secreted form of CE2 that was
capable to convert the prodrug CPT-11, leading to enhanced toxi-
city of CPT-11 to colon cancer cells. This construct holds promise
in GDEPT approaches since transduction of tumour cells with
psCE2 will most likely result in high concentrations of sCE2
throughout the whole tumour. Therefore, CPT-11 will be
converted to SN-38 very efﬁciently throughout the tumour, result-
ing in a larger bystander effect than intracellular conversion of
CPT-11. The C28-sCE2 fusion protein is as active as sCE2, and
therefore this construct is as useful as sCE2 for GDEPT, but the
theoretical advantage of C28-sCE2 is that the targeting moiety will
prevent leakage of the construct into the circulation. However,
from this study it can not be concluded that C28-sCE2 will have
this additional advantage as compared to sCE2. To prove this
hypothesis, in vivo experiments are necessary in which sCE2 and
C28-sCE2 are expressed in colon carcinoma xenografts followed
by CPT-11 administration.
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Figure 5 Cytotoxicity assay with the EpCAM expressing cell line SW1398 incubated with 1 mM CPT-11 and concentrated supernatants of COS-7 cells
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